Zealand Pharma major shareholder announcement: Polar Capital
Zealand Pharma (Nasdaq: ZEAL) received a notification from major shareholder Polar Capital on October 11, 2022. As of October 10, Polar Capital holds 5,930,317 shares, representing 11.51% of Zealand's total share capital and voting rights. Zealand Pharma is a biotechnology company focused on developing innovative peptide-based medicines, with a successful portfolio of drug candidates, including two on the market and three in late-stage development.
- Polar Capital holds 11.51% of total shares, indicating strong shareholder interest.
- Zealand has two marketed drug candidates and three in late-stage development, showcasing its robust pipeline.
- None.
Company announcement – No. 47 / 2022
Zealand Pharma major shareholder announcement: Polar Capital
Copenhagen, Denmark and Boston, MA, 11 October 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 11 October 2022 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:
As of 10 October 2022, Polar Capital LLP holds nominally 5,930,317 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to
Please see further details in the attached notification form.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. that includes Boston. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.
Contact:
| Anna Krassowska, PhD Vice President, Investor Relations & Corporate Communications Zealand Pharma Email: ank@zealandpharma.com David Rosen (U.S. Media) Argot Partners Email: media@zealandpharma.com |
Attachment
FAQ
What is the recent shareholder update for Zealand Pharma as of October 2022?
What percentage of Zealand Pharma's shares does Polar Capital hold?
What is the focus of Zealand Pharma's business?
